Acute Myeloid Leukemia

Pathway ID: SIGNOR-AMLView in NDEx

Description: Regardless of its etiology, the pathogenesis of AML involves the abnormal proliferation and differentiation of a clonal population of myeloblasts in bone marrow. These proliferative, abnormally or poorly differentiated myeloid cells infiltrate bone marrow, blood and other tissues. According to the two-hits model, most cases of AML originate from combinations of two mutations that i) activate pro-proliferative pathways (FLT3, K/NRAS, STAT3, JAK2, ABL1 and c-KIT) or affect genomic stability or repair (NPM1, TP53) and ii) mutations impairing normal hematopoietic differentiation (CBF, MLL, EVI1, TEL/ETV6, RARA,TET2, CEBPA) or DNA-methylation related genes (DNMT3A, TET2, IDH-1 and IDH-2).

Curated by: Gianni Cesareni and Alessandro Palma

complexity level

level 1 seed interactions
level 2 connect
level 3 first neighbors
level 4 all
level 5 PPI

69 Seed Entities

Organism:
Name Primary ID
HRAS P01112
CCNA1 P78396
BRAF P15056
alpha-ketoglutarate CID:164533
SP1 P08047
FBXW7 Q969H0
HOXA9 P31269
MEIS1 O00470
PTPN11 Q06124
AML1-ETO SIGNOR-FP1
IKK-complex SIGNOR-C14
CBL P22681
Differentiation SIGNOR-PH37
NFY SIGNOR-C1
ABL1 P00519
PML-RARα SIGNOR-FP2
MLL-AF4 SIGNOR-FP4
MLL-ENL SIGNOR-FP7
MECOM Q03112
CBFβ-MYH11 SIGNOR-FP3
IDH1 O75874
PRC2 SIGNOR-C130
JAK2 O60674
CBFB Q13951
BCR-ABL SIGNOR-FP6
NRAS P01111
MEK1/2 SIGNOR-PF25
Apoptosis SIGNOR-PH2
PtsIns(3,4,5)P3 CID:24755492
CEBPA P49715
CDKN2A P42771
RUNX1 Q01196
RXRA P19793
PDPK1 O15530
KMT2A Q03164
AKT SIGNOR-PF24
NfKb-p65/p50 SIGNOR-C13
WT1 P19544
MYC P01106
AEP complex SIGNOR-C117
ATR Q13535
BCL2 P10415
KITLG P21583
PTPRC P08575
SOS1 Q07889
PIM SIGNOR-PF34
KIT P10721
FLT3 P36888
TET2 Q6N021
JUN P05412
KRAS P01116
NPM1 P06748
Core Binding Factor complex SIGNOR-C214
MEN1 O00255
Proliferation SIGNOR-PH4
GRB2 P62993
FLT3LG P49771
IDH2 P48735
ID1 P41134
DNMT3A Q9Y6K1
PIK3CA P42336
ASXL1 Q8IXJ9
GAB1 Q13480
TP53 P04637
STAT5A P42229
MLL-AF9 SIGNOR-FP5
ERK1/2 SIGNOR-PF1
STAT3 P40763
MDM2 Q00987